載入...
Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, importa...
Na minha lista:
| 發表在: | J Diabetes Res |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Hindawi Publishing Corporation
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4709665/ https://ncbi.nlm.nih.gov/pubmed/26839899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/8352957 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|